Results 11 to 20 of about 60,286 (337)

Cost-effectiveness evaluation based on two models of first-line atezolizumab monotherapy and chemotherapy for advanced non-small cell lung cancer with high-PDL1 expression

Frontiers in Oncology, 2023
BackgroundAtezolizumab may provide clinical benefits to patients with advanced non-small cell lung cancer (NSCLC). However, the price of atezolizumab is relatively high, and its economic outcomes have remained unclear.
Chuan Zhang, Chuan Zhang, Chuan Zhang, Yue Liu, Jing Tan, Panwen Tian, Weimin Li   +6 more
doaj   +1 more source

Atezolizumab-induced bilateral anterior uveitis: A case report

American Journal of Ophthalmology Case Reports, 2021
Purpose: To report a case of bilateral anterior uveitis undergoing atezolizumab treatment for advanced non-small cell lung cancer (NSCLC). Observations: A 64-year-old man was receiving atezolizumab for metastatic programmed cell death ligand 1 (PD-L1 ...
Tsuyoshi Mito, Shun Takeda, Nozomu Motono, Hiroshi Sasaki   +3 more
doaj   +1 more source

Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)

Journal of Clinical Oncology, 2021
PURPOSE: IMpower133 (ClinicalTrials.gov identifier: NCT02763579), a randomized, double-blind, phase I/III study, demonstrated that adding atezolizumab (anti-programmed death-ligand 1 [PD-L1]) to carboplatin plus etoposide (CP/ET) for first-line (1L ...
Stephen V. Liu, M. Reck, A. Mansfield, T. Mok, A. Scherpereel, N. Reinmuth, M. Garassino, J. de Castro Carpeño, R. Califano, M. Nishio, F. Orlandi, J. Alatorre-Alexander, T. Leal, Ying Cheng, Jong-Seok Lee, S. Lam, M. McCleland, Yu Deng, S. Phan, L. Horn   +19 more
semanticscholar   +1 more source

Targeting autophagy enhances atezolizumab-induced mitochondria-related apoptosis in osteosarcoma

Cell Death and Disease, 2021
In this study, we identified the multifaceted effects of atezolizumab, a specific monoclonal antibody against PD-L1, in tumor suppression except for restoring antitumor immunity, and investigated the promising ways to improve its efficacy.
Zhuochao Liu, Hongyi Wang, Chuanzhen Hu, Chuanlong Wu, Jun Wang, Fangqiong Hu, Yucheng Fu, Junxiang Wen, Weibin Zhang   +8 more
doaj   +1 more source

The ambitious role of anti angiogenesis molecules: Turning a cold tumor into a hot one [PDF]

, 2018
In renal cancer emerging treatment options are becoming available and there is a strong need to combine therapies to reformulate and adjourn clinical practice.
Botticelli, A., Marchetti, P., Nuti, M., Rughetti, A., Zizzari, I. G.   +4 more
core   +1 more source

Multiomics identifies the link between intratumor steatosis and the exhausted tumor immune microenvironment in hepatocellular carcinoma

Hepatology, EarlyView., 2022
Steatotic HCC can be diagnosed by MRI and forms a pro‐tumor immune microenvironment with high expression of PD‐L1, M2 polarization of macrophages and activation of CAFs, which may be a good target for combined immunotherapy. Abstract Background and Aims Immunotherapy has become the standard‐of‐care treatment for hepatocellular carcinoma (HCC), but its ...
Hiroki Murai, Takahiro Kodama, Kazuki Maesaka, Shoichiro Tange, Daisuke Motooka, Yutaka Suzuki, Yasuyuki Shigematsu, Kentaro Inamura, Yoshihiro Mise, Akio Saiura, Yoshihiro Ono, Yu Takahashi, Yota Kawasaki, Satoshi Iino, Shogo Kobayashi, Masashi Idogawa, Takashi Tokino, Tomomi Hashidate‐Yoshida, Hideo Shindou, Masanori Miyazaki, Yasuharu Imai, Satoshi Tanaka, Eiji Mita, Kazuyoshi Ohkawa, Hayato Hikita, Ryotaro Sakamori, Tomohide Tatsumi, Hidetoshi Eguchi, Eiichi Morii, Tetsuo Takehara   +29 more
wiley   +1 more source

A clinical variable‐based nomogram could predict the survival for advanced NSCLC patients receiving second‐line atezolizumab

Cancer Medicine, 2021
Objective A nomogram model based on clinical variables was conducted to predict the survival in patients with non‐small cell lung cancer (NSCLC) receiving second‐line atezolizumab.
Xiaoling Shang, Jianxiang Shi, Xiaohui Wang, Chenglong Zhao, Haining Yu, Haiyong Wang   +5 more
doaj   +1 more source

Adverse reactions of atezolizumab versus durvalumab based on OpenFDA

Zhongguo linchuang yanjiu, 2023
Objective To analyze the adverse drug reactions (ADR) of atezolizumab and durvalumab based on the US Food and Drug Administration Public Data Open Project (OpenFDA) to provide reference for rational clinical use of drugs.
LU Xinglan, ZHAO Feng, ZHOU Qiuyun, WANG Fang, LU Tao   +4 more
doaj   +1 more source

The effect of PD-L1 testing on the cost-effectiveness and economic impact of immune checkpoint inhibitors for the second-line treatment of NSCLC [PDF]

, 2017
Background: Immune checkpoint inhibitors improve outcomes compared with chemotherapy in lung cancer. Tumor PD-L1 receptor expression is being studied as a predictive biomarker. The objective of this study was to assess the cost-effectiveness and economic
Abdel-Rahman, Aguiar, Borghaei, Brahmer, Calhoun, Chen, Dent, Domingues, Doyle, Ferlay, Goeree, Hanahan, Herbst, Herbst, Huang, Hurvitz, Masters, Matter-walstra, Moro-Sibilot, Nafees, Passiglia, Petitti, Rittmeyer, Siegel, Stokes, Tartari   +25 more
core   +3 more sources

c‐Rel–dependent Chk2 signaling regulates the DNA damage response limiting hepatocarcinogenesis

Hepatology, EarlyView., 2022
In response to genotoxic injury, c‐Rel upregulates ATM‐Chk2‐p53 pathway DNA damage proteins to limiting hepatocarcinogenesis. Abstract Background and Aims Hepatocellular carcinoma (HCC) is a leading cause of cancer‐related death. The NF‐κB transcription factor family subunit c‐Rel is typically protumorigenic; however, it has recently been reported as a
Jack Leslie, Jill E. Hunter, Amy Collins, Amelia Rushton, Lauren G. Russell, Erik Ramon‐Gil, Maja Laszczewska, Misti McCain, Marco Y. W. Zaki, Amber Knox, Yixin Seow, Laura Sabater, Daniel Geh, Neil D. Perkins, Helen L. Reeves, Dina Tiniakos, Derek A. Mann, Fiona Oakley   +17 more
wiley   +1 more source